Biocon Ltd Share Price – NSE /  BSE

Pharmaceuticals, Small Cap

The said contracts have been awarded to Duopharma (M) Sendirian Berhad, a wholly-owned subsidiary of Duopharma Biotech.

As part of these contracts, Biocon?s subsidiary, Biocon Sdn. Bhd., Malaysia, will supply short-acting recombinant human insulin, insulin glargine and insulin aspart to Duopharma (M) Sendirian Berhad for distribution.

The contracts comprise a three-year agreement valued at MYR 155.27 million for human insulin, along with two two-year agreements, which consists of MYR 18 million contract for insulin glargine and MYR 52.5 million contract for insulin aspart.

Shreehas Tambe, CEO & managing director, Biocon, said: ?Malaysia has been central to Biocon?s insulin journey for over a decade, anchored by our integrated insulin manufacturing facility in the country ? the largest in Asia.

Our Johor operations enable us to deliver insulin at scale, expanding patient access in Malaysia and around the world.?

Biocon is a global biopharma company dedicated to improving affordable access to therapies for chronic conditions such as diabetes, cancer, and autoimmune diseases.

The company had reported 63.4% drop in consolidated net profit to Rs 126 crore in Q4 FY26 from Rs 344 crore in Q4 FY25. Revenue from operations rose by 2.26% year-on-year (YoY) to Rs 4,517 crore during the period under review.

The scrip shed 0.17% to currently trade at Rs 422.65 on the BSE.

Powered by Capital Market - Live News

Biocon announced that its long-standing partner, Duopharma Biotech Berhad (Duopharma Biotech) via its wholly-owned subsidiary Duopharma (M) Sendirian Berhad, has secured multiple insulin contracts from the Ministry of Health (MoH), Malaysia, valued at over MYR 225 million this year.

As part of these contracts, Biocon's subsidiary, Biocon Sdn. Bhd., Malaysia, will supply short-acting recombinant human insulin, insulin glargine and insulin aspart to Duopharma (M) Sendirian Berhad for distribution, supporting continued access to high-quality, cost-effective insulin therapies for people living with diabetes in Malaysia.

The contracts comprise a three-year agreement valued at ~ MYR 155.27 million for human insulin, along with two 2-year agreements: ~ MYR 18 million for insulin glargine and ~ MYR 52.5 million for insulin aspart.

In line with policies indicated in the 13th Malaysia Plan (RMK-13) and the New Industrial Master Plan 2030 (NIMP 2030), both companies are committed to helping patients with diabetes achieve better healthcare outcomes by ensuring a steady and accessible medicine supply.

Biocon announced that the 48th Annual General Meeting(AGM) of the company will be held on 6 August 2026.

Biocon Ltd gained for a fifth straight session today. The stock is quoting at Rs 430.55, up 2.76% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.33% on the day, quoting at 23767.5. The Sensex is at 75657.84, up 0.34%. Biocon Ltd has gained around 22.75% in last one month.

Meanwhile, Nifty Pharma index of which Biocon Ltd is a constituent, has gained around 9.77% in last one month and is currently quoting at 24551.05, up 0.44% on the day. The volume in the stock stood at 56.13 lakh shares today, compared to the daily average of 46.75 lakh shares in last one month.

The benchmark May futures contract for the stock is quoting at Rs 431.7, up 2.65% on the day. Biocon Ltd is up 26.86% in last one year as compared to a 5.01% slide in NIFTY and a 13.99% slide in the Nifty Pharma index.

The PE of the stock is 285.14 based on TTM earnings ending March 26.

Powered by Capital Market - Live News